Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells

Cancer Research

Volumn 56, Issue 19, 1996, Pages 4430-4437

  Goldwasser, François ^a,b   Shimizu, Tsunehiro ^a   Jackman, Joany ^a   Hoki, Yuko ^a   O'Connor, Patrick M ^a   Kohn, Kurt W ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE; DNA; NOCODAZOLE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; CYCLINE; DNA TOPOISOMERASE; ENZYME INHIBITOR;

ARTICLE; CANCER INHIBITION; CELL CYCLE PHASE; CHEMOSENSITIVITY; COLON CARCINOMA; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPLICON; CARCINOMA; CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; COLON TUMOR; DNA REPAIR; DNA REPLICATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APHIDICOLIN; CAMPTOTHECIN; CARCINOMA; CDC2 PROTEIN KINASE; COLONIC NEOPLASMS; CYCLINS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; G2 PHASE; HUMANS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0029661932     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Slichenmyer, W. J., Rowinsky, E K., Donehower, R. C , and Kaufmann, S H. The current status of camptothecin analogs as anticancer agents J. Natl. Cancer Inst , 85: 271-287, 1993.
2. Masuda, N , Fukuoka, M , Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S , Negoro, S, Nishioka, M , Nakagawa, K., and Takada, M. CPT-11 a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol., 10: 1225-1229, 1992.
3. Shimada, Y , Yoshino, M., Wakui, A., Nakao, I , Futatsuki, K., Sakata, Y , Kambe, M , Taguchi, T , and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer J. Clin Oncol., 11: 909-913, 1993.
4. Lynch, T. J. J., Kalish, L , Strauss, G , Elias, A., Skarin, A , Shulman, L N., Posner, M , and Frei, E R Phase II study of topotecan in metastatic non-small-cell lung cancer J. Clin. Oncol., 12: 347-352, 1994.
5. Potmesil, M Camptothecins from bench research to hospital wards Cancer Res., 54: 1431-1439, 1994.
6. Pommier, Y , and Tanizawa. A Camptothecins mechanism of action and resistance Cancer Invest., 11: 3-6, 1994
7. Chen, A. Y , and Liu, L F. DNA Topoisomerases, essential enzymes and lethal targets. Annu. Rev. Pharmacol Toxicol., 94 194-218, 1994.
8. Gupta, M , Fujimori, A , and Pommier, Y. Eukaryotic DNA topoisomerase I. Biochim Biophys Acta, 1262: 1-14, 1995.
9. Holm, C , Covey, J M , Kerrigan, D , and Pommier. Y Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 49: 6365-6368, 1989.
10. Hsiang, Y-H., Lihou, M G., and Liu, L F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res , 49: 5077-5082, 1989
11. Pommier, Y., Leteurtre, F , Fesen, M , Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G , and Kohn, K W Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors Cancer Invest., 12 530-542, 1994.
12. Avemann, K., Knippers, R., Koller, T., and Sogo, J M. Camptothecin, a specific inhibitor ot type I DNA topoisomerase, induces DNA breakage at replication forks Mol. Cell. Biol., 8 3026-3034, 1988
13. Ryan, A J., Squires, S., Strutt, H L., and Johnson, R. T Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA Nucleic Acids Res., 19: 3295-3300, 1991
14. Goldwasser, F., Bae, I , Valenti, M., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen Cancer Res , 55: 2116-2121, 1995
15. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
16. 1 checkpoint does not increase cell survival following DNA damage. Cancer Res , 53: 4164-4168, 1993.
17. 2. Nature (Lond.), 254: 245-247, 1975
18. 2 arrest in mammalian cells. Mol Cell Biochem., 29: 47-57, 1980.
19. 2 block induced by DNA crosslinking agents and its possible consequences. Biochem. Pharmacol , 37: 2303-2309, 1988
20. Pardee, A B Molecules involved in proliferation of normal and cancer cells: presidential address Cancer Res., 47: 1488-1491, 1987
21. Hartwell, L., and Weinert, T. Checkpoints: controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629-634, 1989
22. O'Connor, P. M., and Kohn, K. W A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells. Semin Cancer Biol., 3: 409-416, 1992.
23. 2 arrest altered regulation of p34 cdc2/cyclin B. Cancer Res , 52: 1992.
24. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y , and Solary, E The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia, 9: 1013-1024, 1995.
25. Kaufmann, W. K , Boyer, J. C., Estabrooks, L. L., and Wilson, S. J. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol. Cell. Biol., 11: 3711-3718, 1991
26. Kohn, K. W , Ewig, R A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In: E C. Friedberg and P. C. Hanawalt (eds.), DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York Marcel Dekker, Inc., 1981
27. Bertrand, R , and Pommier, Y Assessment of DNA damage in mammalian cells by DNA filter elution methodology. In: G. P. Studzinski (ed.), Cell Growth and Apoptosis, Vol. 6, pp 97-117. Newark, NJ: Oxford University Press, 1995
28. Fan, S., Smith, M. L , Rivet, D. J , II, Duba, D., Zhan, Q., Kohn, K W , Fornace, A. J J , and O'Connor, P M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Res., 55, 1649-1654, 1995.
29. Covey, J. M., D'Incalci, M., Tilchen, E. J , Zaharko, D. S., and Kohn, K. W Differences in DNA damage produced by incorporation of 5-Aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res., 46: 5511-5517, 1986
30. O'Connor, P M , Ferris, D. K., White, G. A , Pines, J , Hunter, T , Longo, D. L., and Kohn, K. W. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard Cell Growth & Differ., 3: 43-52, 1992.
31. Shimizu, T., O' Connor, P. M., Kohn, K W , and Pommier, Y. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage Cancer Res., 55 228-231, 1995.
32. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I Cancer Res , 49, 5016-5022, 1989.
33. Bertrand, R , and Pommier, Y. Assessment of DNA damage in mammalian cells by DNA filtration methods. Inz G Studzinski (ed), Cell Growth and Apoptosis: A Practical Approach, pp. 96-117. Oxford, United Kingdom IRL Press, 1995.
34. O'Connor, P M , Jackman, J., Jondle, D., Bhatia, K , Magrath, I., and Kohn, K. W Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines Cancer Res., 53: 4776-4780, 1993.
35. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W Participation of p53 in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1992.
36. Sugimoto, Y., Tsukahara, S , Oh-hara, T , Isoe, T , and Tsuruo, T Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by monoclonal antibody Cancer Res., 50 6925-6930, 1990
37. Fujimori, A , Harker, W G., Kohlhagen, G., Hoki, Y., and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res , 55: 1339-1346, 1995.
38. Andoh, T., Ishii, K., Suzuki, Y , Ikegami, Y., Kusunki, Y , Takemoto, Y., and Okada, K Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I, Proc Natl. Acad. Sci USA, 84: 5565-5569, 1987
39. Tamura, H-O , Kohchi, C., Yamada, R., Ikeda, T , Koiwa, O., Patterson, E., Keene, J. D , Okada, K , Kjeldsen, E., Nishikawa, K., and Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res , 19: 69-75, 1991.
40. Tanizawa, A , Bertrand, R., Kohlhagen, G , Tabuchi, A., Jenkins, J , and Pommier, Y Cloning of Chinese Hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem., 268 25463-25468, 1993.
41. Benedetti, P., Fioranti, P., Capuani, L., and Wang, J C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res., 53: 4343-4348, 1993
42. Rubin, E , Pantazis, P., Toppmeyer, D., Giovanella, B , and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic and resistance to 9-nitro-camptothecin J. Biol Chem , 269: 2433-2439, 1994.
43. Perego, P , Capranico, G , Supino, R , and Zunino, F Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different types. Anti-Cancer Drugs, 5: 645-649, 1994.
44. Solary, E, Bertrand, R., and Pommier, Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells Leuk. & Lymphoma, 15, 21-32, 1994.
45. Smith, P. J , Makinson, T A , and Watson, J. V. Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I Int. J. Radiat. Biol. 55: 217-231, 1989.
46. Jones, N. J., Ellard, S., Waters, R., and Parry, E. M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. Carcinogenesis (Lond.), 14: 2487-2494, 1993.
47. Squires, S , Dates, D J., and Johnson, R. T. Cockayne's syndrome cells show enhanced sensitivity to deoxyguanosine and camptothecin. Mutagenesis, 5: 76, 1990.
48. Paulovich, A. G , and Hartwell, L. H. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell, 82, 841-847, 1995.
49. Zakian, V. A. ATM-related genes what do they tell us about functions of the human gene. Cell, 82: 685-687, 1995.
50. Weinert, T. A., and Hartwell, L. H Characterization of RAD9 of S. cererisiae and evidence its function acts posttranslationally in cell cycle arrest after DNA damage Mol. Cell Biol., 10, 6554-6564, 1990
51. Hartwell, L H., and Kastan, M B Cell cycle control and cancer. Science (Washington DC), 266: 18212-18215, 1994.
52. Bendixen, C , Thomsen, B , Alsner, J , and Westergaard, O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry, 29 5613-5619, 1990.
53. Pommier, Y , Jenkins, J., Kohlhagen, G., and Leteurtre, F. DNA recombinase activity of eukaryotic DNA topoisomerase I: effects of camptothecin and other inhibitors Mutat Res., 337: 135-145, 1995.
54. 2 delay. Cancer Res., 55, 1643-1648, 1995.
55. 2 checkpoint deficient and competent cells. Cancer Res., 55: 1639-1642, 1995